Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

Rhea-AI Summary

Geron (Nasdaq: GERN), a commercial-stage biopharmaceutical company, has announced that it will release its second quarter 2024 financial results and business highlights on Thursday, August 8, 2024. The company will issue a press release before the market opens, which will be available on their website. Additionally, Geron will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the financial results and business highlights. Interested parties can access the webcast by registering online through the provided link. An archive of the webcast will be available on the company's website for 30 days following the event.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link: https://events.q4inc.com/attendee/182024239

About Geron

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is FDA-approved for the treatment of adult patients with lower-risk MDS with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718991119/en/

Aron Feingold

Vice President, Investor Relations and Corporate Communications

Kristen Kelleher

Associate Director, Investor Relations and Corporate Communications

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When will Geron (GERN) release its Q2 2024 financial results?

Geron (GERN) will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens.

How can investors access Geron's (GERN) Q2 2024 earnings conference call?

Investors can access Geron's Q2 2024 earnings conference call by registering online at https://events.q4inc.com/attendee/182024239. The call is scheduled for 8:00 a.m. ET on August 8, 2024.

Where can I find Geron's (GERN) Q2 2024 financial results press release?

Geron's Q2 2024 financial results press release will be available on the company's website at www.geron.com/investors on August 8, 2024.

How long will the webcast of Geron's (GERN) Q2 2024 earnings call be available?

An archive of the webcast for Geron's Q2 2024 earnings call will be available on the company's website for 30 days following the event.